Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CF 102

Small molecule · developed by Can-Fite BioPharma

Phase 1/2 Most advanced trial (none active)
CANF Developer
1 Registered trials

What is CF 102?

CF 102 (also called Cl-IB-MECA) is a small molecule studied in chronic hepatitis C.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cl-IB-MECA
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Can-Fite BioPharma (CANF)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
Z07JR07J6C

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00790673 Phase 1/2 Chronic Hepatitis C Completed CANF

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis C

More from Can-Fite BioPharma

Namodenoson Phase 3 Piclidenoson Phase 3

Follow CANF, the company behind CF 102

See CANF's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CANF catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.